ATE530523T1 - (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate - Google Patents

(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate

Info

Publication number
ATE530523T1
ATE530523T1 AT07805287T AT07805287T ATE530523T1 AT E530523 T1 ATE530523 T1 AT E530523T1 AT 07805287 T AT07805287 T AT 07805287T AT 07805287 T AT07805287 T AT 07805287T AT E530523 T1 ATE530523 T1 AT E530523T1
Authority
AT
Austria
Prior art keywords
carbazol
tetrahydro
amino
acetic acid
acid derivatives
Prior art date
Application number
AT07805287T
Other languages
English (en)
Inventor
Heinz Fretz
Julien Pothier
Philippe Risch
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE530523T1 publication Critical patent/ATE530523T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07805287T 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate ATE530523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006052723 2006-08-07
PCT/IB2007/053046 WO2008017989A1 (en) 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives

Publications (1)

Publication Number Publication Date
ATE530523T1 true ATE530523T1 (de) 2011-11-15

Family

ID=38805811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07805287T ATE530523T1 (de) 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate

Country Status (27)

Country Link
US (1) US8143304B2 (de)
EP (2) EP2316824A1 (de)
JP (1) JP5220013B2 (de)
KR (1) KR101411820B1 (de)
CN (1) CN101500996B (de)
AR (1) AR062222A1 (de)
AT (1) ATE530523T1 (de)
AU (1) AU2007282949B8 (de)
BR (1) BRPI0715179A2 (de)
CA (1) CA2658986C (de)
CL (1) CL2007002274A1 (de)
CY (1) CY1112276T1 (de)
DK (1) DK2051962T3 (de)
ES (1) ES2374321T3 (de)
HR (1) HRP20120044T1 (de)
IL (1) IL196891A (de)
MA (1) MA30696B1 (de)
MX (1) MX2009001105A (de)
MY (1) MY147588A (de)
NO (1) NO20090979L (de)
NZ (1) NZ574705A (de)
PL (1) PL2051962T3 (de)
PT (1) PT2051962E (de)
RU (1) RU2448092C2 (de)
SI (1) SI2051962T1 (de)
TW (1) TWI408126B (de)
WO (1) WO2008017989A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8501959B2 (en) * 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
PE20120056A1 (es) * 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
PT2558447E (pt) * 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
CN104402798B (zh) * 2014-10-21 2016-09-14 杭州瑞德化工有限公司 一种3-氨基-1，2，3，4-四氢咔唑的拆分方法
WO2016133793A1 (en) 2015-02-16 2016-08-25 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
CN112094223B (zh) * 2019-06-18 2023-09-15 华东师范大学 一类脲基四氢咔唑类小分子有机化合物及用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
US5298626A (en) * 1991-01-18 1994-03-29 Hoechst-Roussel Pharmaceuticals Incorporated Select cyclopent[b]indoles
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5350762A (en) * 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
WO2000063171A1 (en) * 1999-04-20 2000-10-26 Meiji Seika Kaisha, Ltd. Tricyclic compounds
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
GB2380951C (en) 2001-10-18 2011-09-28 Derek Colin Tolley Filtration of liquid media
NZ533430A (en) 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (de) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. PGD-2-Rezetorantagonismus aufweisende Verbindungen
AU2003231513A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1558614B1 (de) 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizin- und pyridoindolizinderivate
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
AU2004240705A1 (en) 2003-05-20 2004-12-02 Merck Frosst Canada & Co. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CA2527773A1 (en) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CA2551778C (en) 2004-01-31 2013-10-22 Actimis Pharmaceuticals, Inc. Imidazo[1,2-c]pyrimidinylacetic acid derivatives
CA2558545C (en) * 2004-03-11 2012-10-16 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
JP5063348B2 (ja) 2004-08-26 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド ２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体
MX2007003336A (es) * 2004-09-21 2007-06-05 Athersys Inc Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos.
AU2005286717A1 (en) 2004-09-21 2006-03-30 Wyeth Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
ES2369782T3 (es) * 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
RU2416601C2 (ru) 2005-02-25 2011-04-20 Оно Фармасьютикал Ко., Лтд. Соединение индола и его применение
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
NZ562772A (en) 2005-05-24 2010-01-29 Serono Lab Tricyclic spiro derivatives as CRTH2 modulators
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP2397476A3 (de) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indolderivat mit PGD2-Rezeptor-Antagonist-Aktivität
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
EP1931632A4 (de) 2005-08-18 2011-05-11 Microbia Inc Nützliche indolverbindungen
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP5220013B2 (ja) 2013-06-26
ES2374321T3 (es) 2012-02-15
KR20090047504A (ko) 2009-05-12
SI2051962T1 (sl) 2012-02-29
TWI408126B (zh) 2013-09-11
DK2051962T3 (da) 2012-01-02
MA30696B1 (fr) 2009-09-01
BRPI0715179A2 (pt) 2013-06-11
KR101411820B1 (ko) 2014-06-24
NO20090979L (no) 2009-05-06
HRP20120044T1 (hr) 2012-02-29
IL196891A (en) 2013-07-31
IL196891A0 (en) 2009-11-18
CY1112276T1 (el) 2015-12-09
TW200817328A (en) 2008-04-16
CA2658986A1 (en) 2008-02-14
AU2007282949A1 (en) 2008-02-14
WO2008017989A1 (en) 2008-02-14
RU2009107889A (ru) 2010-09-20
EP2051962A1 (de) 2009-04-29
CA2658986C (en) 2014-11-25
HK1130062A1 (en) 2009-12-18
EP2316824A1 (de) 2011-05-04
CL2007002274A1 (es) 2008-04-18
PT2051962E (pt) 2012-01-10
RU2448092C2 (ru) 2012-04-20
MY147588A (en) 2012-12-31
EP2051962B1 (de) 2011-10-26
MX2009001105A (es) 2009-02-10
PL2051962T3 (pl) 2012-03-30
US20100190830A1 (en) 2010-07-29
AU2007282949B2 (en) 2012-08-30
CN101500996A (zh) 2009-08-05
AR062222A1 (es) 2008-10-22
AU2007282949B8 (en) 2012-10-04
NZ574705A (en) 2011-12-22
JP2010500337A (ja) 2010-01-07
US8143304B2 (en) 2012-03-27
CN101500996B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
ATE530523T1 (de) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
PT2097111E (pt) Heterodímeros de ácido glutámico
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
EP2115141A4 (de) miRNA AUS INVERTEBRATEN
EP1973405A4 (de) Hydroxyalkylarylamid-derivate
NL2000537A1 (nl) Aminederivaten.
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
EP1976511A4 (de) Fluorierte arylamid-derivate
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
ATE512135T1 (de) Spiroindolinonderivate
BRPI0810646A2 (pt) " compostos farmacêuticos ".
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
DK2035394T3 (da) 2-pyrazincarboxamidderivater
EP2291078A4 (de) Oxazolbenzimidazolderivate
NO20085127L (no) Leptomycinderivater
NL2000527A1 (nl) Dibenzylamine-verbindingen en -derivaten.
CR10353A (es) Nuevos compuestos.
EP2279532A4 (de) Oxazolbenzimidazolderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2051962

Country of ref document: EP